
|Videos|October 9, 2021
Results from phase 3 YOSEMITE and RHINE trials on faricimab in DMO
Author(s)OTE Staff Reports
Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021.
Advertisement
Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021. In her presentation, Dr Baumal highlights results from the Phase 3 YOSEMITE and RHINE trials.
The American Society of Retina Specialists (ASRS) is hosting its 39th Annual Scientific Meeting from 8-12 October 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Related Content:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: BRUNELLO 1-year results for remigromig in DME
2
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
3
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5


















